Joseph F Goldberg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5822604/publications.pdf Version: 2024-02-01



LOSEDH F COLDREDC

#	Article	IF	CITATIONS
1	The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders. American Journal of Psychiatry, 2013, 170, 1249-1262.	4.0	579
2	Impact of childhood abuse on the clinical course of bipolar disorder. British Journal of Psychiatry, 2005, 186, 121-125.	1.7	343
3	Preliminary Randomized, Double-Blind, Placebo-Controlled Trial of Pramipexole Added to Mood Stabilizers for Treatment-Resistant Bipolar Depression. American Journal of Psychiatry, 2004, 161, 564-566.	4.0	305
4	Risk for Bipolar Illness in Patients Initially Hospitalized for Unipolar Depression. American Journal of Psychiatry, 2001, 158, 1265-1270.	4.0	279
5	Manic Symptoms During Depressive Episodes in 1,380 Patients With Bipolar Disorder: Findings From the STEP-BD. American Journal of Psychiatry, 2009, 166, 173-181.	4.0	263
6	Adjunctive Antidepressant Use and Symptomatic Recovery Among Bipolar Depressed Patients With Concomitant Manic Symptoms: Findings From the STEP-BD. American Journal of Psychiatry, 2007, 164, 1348-1355.	4.0	185
7	Identifying and treating cognitive impairment in bipolar disorder. Bipolar Disorders, 2009, 11, 123-137.	1.1	145
8	Features Associated With the Delayed Initiation of Mood Stabilizers at Illness Onset in Bipolar Disorder. Journal of Clinical Psychiatry, 2002, 63, 985-991.	1.1	145
9	Consistency of remission and outcome in bipolar and unipolar mood disorders: a 10-year prospective follow-up*1. Journal of Affective Disorders, 2004, 81, 123-131.	2.0	140
10	Depressive Illness Burden Associated With Complex Polypharmacy in Patients With Bipolar Disorder. Journal of Clinical Psychiatry, 2009, 70, 155-162.	1.1	130
11	Assessing cognitive deficits in bipolar disorder: Are self-reports valid?. Psychiatry Research, 2005, 136, 43-50.	1.7	128
12	Self-Reported History of Manic/Hypomanic Switch Associated With Antidepressant Use. Journal of Clinical Psychiatry, 2007, 68, 1472-1479.	1.1	120
13	Association of Recurrent Suicidal Ideation With Nonremission From Acute Mixed Mania. American Journal of Psychiatry, 1998, 155, 1753-1755.	4.0	101
14	Bipolar Disorder With Comorbid Cluster B Personality Disorder Features. Journal of Clinical Psychiatry, 2005, 66, 339-345.	1.1	100
15	Guidelines for the recognition and management of mixed depression. CNS Spectrums, 2017, 22, 203-219.	0.7	97
16	Subjective life satisfaction and objective functional outcome in bipolar and unipolar mood disorders: A longitudinal analysis. Journal of Affective Disorders, 2005, 89, 79-89.	2.0	95
17	Clinical features related to age at onset in bipolar disorder. Journal of Affective Disorders, 2004, 82, 21-27.	2.0	91
18	The Association Between Substance Abuse and Antidepressant-Induced Mania in Bipolar Disorder. Journal of Clinical Psychiatry, 2002, 63, 791-795.	1.1	89

Joseph F Goldberg

#	Article	IF	CITATIONS
19	Development of posttraumatic stress disorder in adult bipolar patients with histories of severe childhood abuse. Journal of Psychiatric Research, 2005, 39, 595-601.	1.5	81
20	Recurrent Affective Syndromes in Bipolar and Unipolar Mood Disorders at Follow-Up. British Journal of Psychiatry, 1995, 166, 382-385.	1.7	76
21	Predictors of trait aggression in bipolar disorder. Bipolar Disorders, 2008, 10, 285-292.	1.1	72
22	Overdiagnosis of Bipolar Disorder Among Substance Use Disorder Inpatients With Mood Instability. Journal of Clinical Psychiatry, 2008, 69, 1751-1757.	1.1	71
23	Assessing Cognitive Function in Bipolar Disorder: Challenges and Recommendations for Clinical Trial Design. Journal of Clinical Psychiatry, 2015, 76, e342-e350.	1.1	63
24	Cognitive Dysfunction in Bipolar Disorder. CNS Drugs, 2007, 21, 971-981.	2.7	55
25	A 15-year prospective follow-up of bipolar affective disorders: comparisons with unipolar nonpsychotic depression. Bipolar Disorders, 2011, 13, 155-163.	1.1	54
26	Development and reliability of the HAM-D/MADRS Interview: An integrated depression symptom rating scale. Psychiatry Research, 2006, 145, 21-37.	1.7	50
27	Predicting Hospitalization Versus Discharge of Suicidal Patients Presenting to a Psychiatric Emergency Service. Psychiatric Services, 2007, 58, 561-565.	1.1	41
28	Long-term remission and recovery in bipolar disorder: A review. Current Psychiatry Reports, 2005, 7, 456-461.	2.1	38
29	Age at onset of bipolar disorder and risk for comorbid borderline personality disorder. Bipolar Disorders, 2009, 11, 205-208.	1.1	37
30	Benefits and limitations of antidepressants and traditional mood stabilizers for treatment of bipolar depression. Bipolar Disorders, 2005, 7, 3-12.	1.1	36
31	Effect of Sublingual Dexmedetomidine vs Placebo on Acute Agitation Associated With Bipolar Disorder. JAMA - Journal of the American Medical Association, 2022, 327, 727.	3.8	36
32	Six-Month Prospective Life Charting of Mood Symptoms with Lamotrigine Monotherapy Versus Placebo in Rapid Cycling Bipolar Disorder. Biological Psychiatry, 2008, 63, 125-130.	0.7	35
33	THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY SURVEY OF PSYCHOPHARMACOLOGISTS' PRACTICE PATTERNS FOR THE TREATMENT OF MOOD DISORDERS. Depression and Anxiety, 2015, 32, 605-613.	2.0	34
34	Dysfunctional Attitudes and Cognitive Schemas in Bipolar Manic and Unipolar Depressed Outpatients. Journal of Nervous and Mental Disease, 2008, 196, 207-210.	0.5	31
35	Parsing trait and state effects of depression severity on neurocognition: Evidence from a 26-year longitudinal study Journal of Abnormal Psychology, 2012, 121, 830-837.	2.0	30
36	Suicidal Ideation and Pharmacotherapy Among STEP-BD Patients. Psychiatric Services, 2005, 56, 1534-1540.	1.1	28

#	Article	IF	CITATIONS
37	Psychiatry's Niche Role in the COVID-19 Pandemic. Journal of Clinical Psychiatry, 2020, 81, .	1.1	26
38	Hypomania: hype <i>or</i> mania?. Bipolar Disorders, 2010, 12, 758-763.	1.1	25
39	Bipolar Mixed Episodes: Characteristics and Comorbidities. Journal of Clinical Psychiatry, 2007, 68, e25.	1.1	24
40	Effectiveness of quetiapine in rapid cycling bipolar disorder: A preliminary study. Journal of Affective Disorders, 2008, 105, 305-310.	2.0	22
41	Mood Stabilization and Destabilization During Acute and Continuation Phase Treatment for Bipolar I Disorder With Lamotrigine or Placebo. Journal of Clinical Psychiatry, 2009, 70, 1273-1280.	1.1	19
42	Thought Disorder in Schizophrenia and Mania: Impaired Context. Schizophrenia Bulletin, 2000, 26, 879-891.	2.3	18
43	Placing transdermal selegiline for major depressive disorder into clinical context: Number needed to treat, number needed to harm, and likelihood to be helped or harmed. Journal of Affective Disorders, 2013, 151, 409-417.	2.0	18
44	Revising <i>Diagnostic and Statistical Manual of Mental Disorders</i> , Fifth Edition, criteria for the bipolar disorders: Phase I of the AREDOC project. Australian and New Zealand Journal of Psychiatry, 2018, 52, 1173-1182.	1.3	18
45	A Systematic Review of Complex Polypharmacy in Bipolar Disorder. Journal of Clinical Psychiatry, 2021, 82, .	1.1	16
46	Clinician-Rated Versus Self-Rated Screening for Bipolar Disorder Among Inpatients With Mood Symptoms and Substance Misuse [CME]. Journal of Clinical Psychiatry, 2012, 73, 1525-1530.	1.1	14
47	Monoamine Oxidase Inhibitors Revisited: What You Should Know. Journal of Clinical Psychiatry, 2013, 74, 189-191.	1.1	13
48	A Modified Delphi Consensus Study of the Screening, Diagnosis, and Treatment of Tardive Dyskinesia. Journal of Clinical Psychiatry, 2020, 81, .	1.1	13
49	A Case of Akathisia After Switching From Branded to Generic High-Dose Olanzapine. Journal of Clinical Psychiatry, 2012, 73, 497.	1.1	12
50	Identifying Profiles of Patients With Bipolar I Disorder Who Would Benefit From Maintenance Therapy With a Long-Acting Injectable Antipsychotic. Journal of Clinical Psychiatry, 2020, 81, .	1.1	12
51	Do we need to flick the switch? The need for a broader conceptualization of iatrogenic course aggravation in clinical trials of bipolar disorder. Psychiatry and Clinical Neurosciences, 2010, 64, 367-371.	1.0	11
52	How Should Psychiatry Respond to COVID-19 Anti-Vax Attitudes?. Journal of Clinical Psychiatry, 2021, 82, .	1.1	11
53	Overall Diagnostic Assessment of Mixed Episodes in Bipolar Disorder. CNS Spectrums, 2009, 14, 4-7.	0.7	10
54	Development and psychometric evaluation of the Bipolar Functional Status Questionnaire (BFSQ). Bipolar Disorders, 2010, 12, 32-44.	1.1	10

#	Article	IF	CITATIONS
55	What should ICD-11 do that DSM-5 did not?. Australian and New Zealand Journal of Psychiatry, 2014, 48, 87-88.	1.3	10
56	The bipolar disorders: A case for their categorically distinct status based on symptom profiles. Journal of Affective Disorders, 2020, 277, 225-231.	2.0	10
57	Major depressive disorder with mixed features and treatment response to lurasidone: A symptom network model. Journal of Affective Disorders, 2020, 277, 1045-1054.	2.0	10
58	Do You Order Pharmacogenetic Testing? Why?. Journal of Clinical Psychiatry, 2017, 78, 1155-1156.	1.1	10
59	Mixed Depression: A Farewell to Differential Diagnosis?. Journal of Clinical Psychiatry, 2015, 76, e378-e380.	1.1	9
60	Differential Diagnosis of Major Depressive Disorder Versus Bipolar Disorder. Journal of Clinical Psychiatry, 2019, 80, .	1.1	9
61	Letter to the Editor: Clinical versus statistical significance of pharmacogenomic-guided antidepressant therapy: What's really being measured and marketed?. Journal of Psychiatric Research, 2019, 114, 208-209.	1.5	8
62	Differentiating mania/hypomania from happiness using a machine learning analytic approach Journal of Affective Disorders, 2021, 281, 505-509.	2.0	8
63	Core Concepts Involving Adverse Psychotropic Drug Effects. Psychiatric Clinics of North America, 2016, 39, 375-389.	0.7	7
64	Antidepressants: The scapegoat of poor outcome bipolar disorder?. Australian and New Zealand Journal of Psychiatry, 2012, 46, 302-305.	1.3	6
65	Remission and recovery associated with lurasidone in the treatment of major depressive disorder with subthreshold hypomanic symptoms (mixed features): post-hoc analysis of a randomized, placebo-controlled study with longer-term extension. CNS Spectrums, 2017, 22, 220-227.	0.7	6
66	Complex Combination Pharmacotherapy for Bipolar Disorder: Knowing When Less Is More or More Is Better. Focus (American Psychiatric Publishing), 2019, 17, 218-231.	0.4	6
67	The modern pharmacopoeia: a return to depressive realism?. Bipolar Disorders, 2008, 10, 969-972.	1.1	5
68	Ruling in and ruling out â€~caseness' in the bipolar spectrum: implications for initial screening. Bipolar Disorders, 2010, 12, 539-540.	1.1	5
69	A preliminary open trial of nefazodone added to mood stabilizers for bipolar depression. Journal of Affective Disorders, 2013, 144, 176-178.	2.0	5
70	Electroconvulsive therapy: still the gold standard for highly treatment-resistant mood disorders. CNS Spectrums, 2022, 27, 525-526.	0.7	5
71	Wrestling With Antidepressant Use in Bipolar Disorder. Journal of Clinical Psychiatry, 2021, 82, .	1.1	4
72	Does Pharmacogenomic Testing Meaningfully Improve Antidepressant Treatment Outcomes When Looking Only at Patients Taking Phase I Hepatically Metabolized Drugs? A Little. Journal of Clinical Psychiatry, 2019, 80, .	1.1	4

#	Article	IF	CITATIONS
73	The Economic and Social Burden of Bipolar Disorder. , 2002, , 441-501.		3
74	Differential Diagnosis of Bipolar Disorder. CNS Spectrums, 2010, 15, 4-7.	0.7	3
75	Optimizing treatment outcomes in bipolar disorder under ordinary conditions. Journal of Clinical Psychiatry, 2008, 69 Suppl 3, 11-9.	1.1	3
76	What psychotherapists should know about pharmacotherapies for bipolar disorder. Journal of Clinical Psychology, 2007, 63, 475-490.	1.0	2
77	That which we call a mood stabilizer: What's in a name?. Australian and New Zealand Journal of Psychiatry, 2017, 51, 866-867.	1.3	2
78	Addressing the unmet needs of current antidepressants: does neuroscience help or hinder clinical psychopharmacology research?. Expert Opinion on Pharmacotherapy, 2017, 18, 1417-1420.	0.9	2
79	Personalized Pharmacotherapy for Bipolar Disorder: How to Tailor Findings From Randomized Trials to Individual Patient-Level Outcomes. Focus (American Psychiatric Publishing), 2019, 17, 206-217.	0.4	2
80	Parsing the effects of comorbid adult ADHD and substance misuse on affective lability in bipolar disorder. Journal of Affective Disorders, 2020, 266, 338-340.	2.0	2
81	What Constitutes Evidence-Based Pharmacotherapy for Bipolar Disorder? Part 1: First-Line Treatments. Journal of Clinical Psychiatry, 2007, 68, 1982-1983.	1.1	2
82	Major depression is a serious and potentially fatal brain syndrome requiring pharmacotherapy or neuromodulation, and psychotherapy. Psychological Medicine, 2022, , 1-3.	2.7	2
83	Expanding the bipolar construct while preserving its diagnostic integrity: are we keeping the baby or the bathwater?. World Psychiatry, 2011, 10, 187-188.	4.8	1
84	How Much Is the Debate Over Antidepressant Efficacy and Safety in Bipolar Depression an Artifact of Study Methodologies?. Journal of Clinical Psychiatry, 2021, 82, .	1.1	1
85	Categorical differentiation of the unipolar and bipolar disorders. Psychiatry Research, 2021, 297, 113719.	1.7	1
86	Diagnosis and Pharmacotherapy of Bipolar Depression in Adults. Journal of Clinical Psychiatry, 2021, 82, .	1.1	1
87	Impact of Childhood Trauma Histories Versus Recent Trauma Symptoms on Affective Lability in Adult Bipolar Disorder. Journal of Clinical Psychiatry, 2021, 82, .	1.1	1
88	When Further Pharmacotherapy Seems Futile. Journal of Clinical Psychiatry, 2018, 80, .	1.1	1
89	What Constitutes Evidence-Based Pharmacotherapy for Bipolar Disorder? Part 2: Complex Presentations and Clinical Context. Journal of Clinical Psychiatry, 2008, 69, 495-496.	1.1	1
90	The Role of Divalproex Plus Olanzapine in Outpatient Mixed-Episode Bipolar I Disorder. Journal of Clinical Psychiatry, 2009, 70, 1548-1550.	1.1	1

#	Article	IF	CITATIONS
91	Pharmacogenomics and antidepressants: efficacy and adverse drug reactions. , 2022, , 189-202.		1
92	Management commentary. , 2008, , 247-251.		0
93	Selected papers from the Sixth International Conference on Bipolar Disorder: from epidemiology to endophenotypes to advances in therapeutics. Bipolar Disorders, 2007, 9, 315-317.	1.1	0
94	Is there life after diagnostic death?. Australian and New Zealand Journal of Psychiatry, 2014, 48, 1167-1168.	1.3	0
95	Should we reserve big gun antimanic drugs for only big gun manias?. Bipolar Disorders, 2018, 20, 7-8.	1.1	0
96	145 Improving Management of Mood Disorders Through an Online Interactive Patient Case Challenge. CNS Spectrums, 2018, 23, 90-91.	0.7	0
97	Applying Evidence-Based Principles to the Treatment of Bipolar Disorder. Focus (American Psychiatric) Tj ETQq1	1 0,7843 0.4	14 rgBT /Overl
98	The Role of Antidepressants in Managing Bipolar II Disorder. , 2019, , 113-128.		0
99	Adjunctive Mood Stabilizers Are Not the Same as a Placebo-Only Arm in Bipolar Depression Trials. Journal of Clinical Psychiatry, 2021, 82, .	1.1	0
100	Individualizing Treatment Selection for Pediatric and Adult Patients With Bipolar Depression. Journal of Clinical Psychiatry, 2021, 82, .	1.1	0
101	Lowering the Diagnostic Threshold for Bipolar Disorder: The Wrong Stuff?. Journal of Clinical Psychiatry, 2012, 73, 443-444.	1.1	Ο
102	The Intersection of Symptomatology in Adult ADHD and Bipolar Disorder. Psychiatric Annals, 2013, 43, 20-25.	0.1	0
103	Efficacy of Varenicline for Smoking Cessation in Bipolar Disorder. Journal of Clinical Psychiatry, 2014, 75, 773-774.	1.1	Ο
104	New Mechanisms, New Opportunities. Journal of Clinical Psychiatry, 2019, 80, .	1.1	0
105	Are (Some) Antipsychotics Depressogenic in Bipolar Disorder?. Journal of Clinical Psychiatry, 2020, 81,	1.1	0
106	What to Do When Your Depressed Patient Develops Mania. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2016, 33, 26S-33S.	0.6	0
107	Ketamine and Cognitive Function in Depression. Journal of Clinical Psychiatry, 2022, 83, .	1.1	Ο
108	Recognizing Impaired Decisional Capacity in Vaccine Refusal. Journal of Clinical Psychiatry, 2022, 83, .	1.1	0

#	Article	IF	CITATIONS
109	Development and validation of a new scale to measure chronic suicidal ideation: The Chronic Suicidal Ideation Inventory-5 (CSI-5). Journal of Psychiatric Research, 2022, 150, 160-164.	1.5	0